Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15440653 | 0.92 | ACHE (0.49) | ACHEP2RX3PRKCIMTORHDAC1 | |
| SCHEMBL15440686 | 0.91 | ACHE (0.49) | ACHEP2RX3MTORTLR9ACKR3 | |
| SCHEMBL18303742 | 0.83 | ESR2 (0.45) | ACHEMTORHDAC1HDAC6MKNK1 | |
| SCHEMBL31138446 | 0.82 | MTOR (0.39) | ACHEPARP1TNKS2PARP2P2RX3 | |
| SCHEMBL25324925 | 0.82 | P2RX3 (0.47) | ACHEPARP1TNKS2PARP2P2RX3 | |
| SCHEMBL31246476 | 0.81 | PARP1 (0.47) | PARP1TNKS2PARP2PRKCIMTOR | |
| SCHEMBL25574315 | 0.81 | PARP1 (0.47) | PARP1TNKS2PARP2PRKCIMTOR | |
| SCHEMBL15421215 | 0.81 | VCP (0.63) | — | |
| SCHEMBL15440470 | 0.80 | ACHE (0.44) | ACHEP2RX3HDAC1HDAC6TLR9 | |
| SCHEMBL21758756 | 0.80 | PARP1 (0.49) | PARP1TNKS2PARP2PRKCIMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-2875018-B1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-3208270-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-9062026-B2 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 | CLEAVE BIOSCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062026-B2 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 | CLEAVE BIOSCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | ACHE 4363/4885PARP1 1237/4885TNKS2 767/4885 |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | PSMG3, PSMD1, PSMD3 | ACHE 3841/4885PARP1 1272/4885TNKS2 588/4885 |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | ACHE 4363/4885PARP1 1237/4885TNKS2 767/4885 |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | PSMG3, PSME1, PSMB1 | ACHE 4363/4885PARP1 1237/4885TNKS2 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.